teratogenicity dr.elza

60
DRUG INTERACTION By Dr . Elza Emmanuel

Upload: elza-emmannual

Post on 18-Aug-2015

21 views

Category:

Health & Medicine


2 download

TRANSCRIPT

Page 1: Teratogenicity dr.elza

DRUG INTERACTION

By Dr . Elza Emmanuel

Page 2: Teratogenicity dr.elza

DEFINITION

MODIFICATION OF RESPONSE TO ONE DRUG BY

ANOTHER WHEN THEY ARE ADMINISTERED

SIMULTANIOUSLY OR IN QUICK SUCCESSION ie,

THE EFFECTS OF ONE DRUG ARE AFFECTED BY

THE EFFECT OF ANOTHER DRUG.

Page 3: Teratogenicity dr.elza

Severity of drug interacton in most cases is highly unpredictable

The doctor must know which drugs are not to be prescribed concurrently

Page 4: Teratogenicity dr.elza

PRECIPITANT DRUG-THE DRUG

THAT PRECIPITATE AN INTERACTION

OBJECT DRUG-THE DRUG WHOSE

ACTION IS AFFECETED

Page 5: Teratogenicity dr.elza

MECHANIISM OF DRUG INTERACTION

1. Pharmacokinetic

2. Pharmacodynamic

Page 6: Teratogenicity dr.elza

PHARMACOKINETIC INTERACTIONS

These interactions alter the concentration of the object drug at its site of action by affecting its absorption,distribution,metabolism or excretion

Page 7: Teratogenicity dr.elza

ABSORPTION

Due to formation of insoluble &poorly absorbed complexes in the gut lumen

Eg:Btw Tetracyclines & calcium/iron salts

Can be minimized by administering two drugs with a gap of 2-3 hours

Page 8: Teratogenicity dr.elza

DISTRIBUTION

Due to displacement of one drug from its binding sites on plasma proteins by another drug

Eg:Quinidine & Digoxin

Page 9: Teratogenicity dr.elza

METABOLISM

Certain drugs reduce or enhance the rate of metabolism of other drugs

Eg:Microsomal enzyme inducers like barbiturates, rifampicin can cause contraceptive failure

Page 10: Teratogenicity dr.elza

EXCRETION

Important in case of drugs actively secreted by tubular transport mechanisms

Eg:Probenacid inhibits tubular secretion of penicillins &cephalosporins and prolongs their plasma t1/2

Page 11: Teratogenicity dr.elza

PHARMACODYNAMIC INTERACTIONS

These interactions are due to modification of action of one drug at the target site by another drug independent of change in its concentration

This results in Enhanced response-SYNERGISM Attenuated response-

ANTAGONISM Abnormal response

Page 12: Teratogenicity dr.elza

EXAMPLES

Fall in BP & MI due to use of sildinafil by patients receiving organic nitrates

Severe hyperkalaemia by concurrent use of ACE inhbitors & K+ sparing diuretics

Additive ototoxicity due to use of aminoglycoside in patient receiving furosemide

Page 13: Teratogenicity dr.elza

DRUG INTERACTIONS BEFORE ADMINISTRATION

Certain drugs react with each other and get inactivated if their solutions are mixed before administration

Eg:Penicilln G/Ampicillin +Gentamicin Thiopentone

sodium+Succinylcholine

Page 14: Teratogenicity dr.elza

ADVERSE DRUG REACTION

Page 15: Teratogenicity dr.elza
Page 16: Teratogenicity dr.elza

EXPECTED UNDESIRABLE EFFECTSTYPE A ADRS

Page 17: Teratogenicity dr.elza

SIDE EFFECTS

These are undesirable effects which are observed even with the therapeutic doses of the drug

They are usually mild and manageable Eg:Promethazine has antiallergic action

-Desirable effect,but it also produces sedation in therapeutic doses-Side effect

Page 18: Teratogenicity dr.elza

SECONDARY EFFECTS

These are indirect consequences of the main pharmacodynamic action of the drug

Eg:Development of superinfection after suppression of bacterial flora by antibiotics

Page 19: Teratogenicity dr.elza

TOXICITY

These are exaggerated form of side effects which occur due to overdoses or after prolonged use of the drug

Eg:Bleeding due to high doses of heparin

Page 20: Teratogenicity dr.elza

UNEXPECTED UNDESIRABLE EFFECTS/TYPE B ADRS/BIZZARRE EFFECTS

Page 21: Teratogenicity dr.elza

DRUG ALLERGY[HYPERSENSITIVITY REACTIONS]

Allergic responses to drug occur when there has been previous exposure to drug & when this sensitised individual is re-exposed to the same drug again

Drugs may elicit Type I,II,III & IV Hypersensitivity reactions.

Page 22: Teratogenicity dr.elza

TYPE I HSR

Allergy develops with in minutes & lasts for 2-3 hour Drug causes formation of tissue sensitizing IgE

antibodies that are fixed to mast cells or leucocytes. The subsequent exposure to drug degranulates

mast cells or activates leucocytes with release of chemical mediators [histamine,serotonin] of allergy

The patient if untreated suddenly passes into anaphylactic shock.

Eg:Anaphylaxis after parenteral administration of penicillin or radiocontrast media

Page 23: Teratogenicity dr.elza

TYPE II HSR

It results when a drug binds to RBC & is recognised by IgG Ab.

The Ag-Ab reaction triggers the lysis of RBC by complement activation /action of cytotoxic T cell/phagocytosis by macrophages.

Results within 72 hr of drug administration

Eg:Drug induced Thrombocytopenia,SLE after quinidine use

Page 24: Teratogenicity dr.elza

TYPE III HSR

Ag-Ab form complexes which are deposited on vascular endothelium & activate complement

Eg:Glomerularnephritis after giving NSAID

Page 25: Teratogenicity dr.elza

TYPE IV HSR

These reactions are mediated by sensitised T cells following contact with an antigen

Sensitised T cells results in release of cytokines which activate macrophages,granulocytes & natural killer cells

Eg:Contact dermatitis ,Photosensitivity.

Page 26: Teratogenicity dr.elza

GENETICALLY DETERMINED ADVERSE EFFECTS

Drug reactions in some individuals may be qualitatively different from effects usually observed from majority of subjects

The mechanism is of genetic origin Eg:The genotype with atypical

pseudocholine esterases cannot hydrolyse succinylcholine,in that case even the therapeutic dose of sccinylcholine leads to prolonged respiratory failure

Page 27: Teratogenicity dr.elza

IDIOSYNCRATIC DRUG RESPONSES

These are harmful & sometimes fatal reactions that occur in a small minority of individuals,for which the cause is yet poorly understood.

Eg:Malignant Hyperthermia on using halothane ,succinylcholine

Page 28: Teratogenicity dr.elza

TYPE –C [CHRONIC EFFECTS]

Adverse effects that are associated with prolonged use of drug.

Eg:Cushing syndrome after chronic use of prednisolone

Page 29: Teratogenicity dr.elza

TYPE-D[DELAYED EFFECTS]

Adverse effects that occur in patients years after treatment or effects appearing in their children who did not receive the treatment

Eg:Clear cell carcinoma of vagina in the daughters of women who took diethylstilbesterol during pregnancy

Page 30: Teratogenicity dr.elza

TERATOGENICITY

By Dr . Elza Emmanuel

Page 31: Teratogenicity dr.elza

DEFINITION

Capacity of a drug to cause fetal abnormalities when administered to pregnant mother.

Page 32: Teratogenicity dr.elza

The placenta does not strictly constitute a barrier and any drug can cross it to a greater or lesser extent.

Page 33: Teratogenicity dr.elza

FACTORS THAT DETERMINE THE EFFECTS OF TERATOGENS1. Point in development

when drug exposure occurs

2. Duration of exposure3. Susceptibility of fetus4. Dose reaching fetus

Page 34: Teratogenicity dr.elza

Drugs can affect fetus at 3 stages

Page 35: Teratogenicity dr.elza

1. Fertilization & implantation -conception to 17 days- failure of pregnancy

2. Organogenesis-18 to 55 days- deformities -MOST VULNERABLE PERIOD

3. Growth & development- 56 days onwards-developmental & functional abnormalities.

Page 36: Teratogenicity dr.elza

MECHANISM OF TERATOGENICITY Poorly understood Multifactorial 1.Drugs directly affect the process

of differentiation 2.Drugs may interfere with the

passage of oxygen & nutrients through placenta

3.Deficiency of a critical substance

Page 37: Teratogenicity dr.elza

FDA USE-IN-PREGNANCY RATINGS

Page 38: Teratogenicity dr.elza

CATEGORY -A

Controlled studies show no risk

Adequate, well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester of pregnancy.

Page 39: Teratogenicity dr.elza

CATEGORY -B

No evidence of risk in humansAdequate, well-controlled studies in

pregnant women have not shown an increased risk of fetal abnormalities despite adverse findings in animals, or, in the absence of adequate human studies, animal studies show no fetal risk. The chance of fetal harm is remote, but remains a possibility. 

Page 40: Teratogenicity dr.elza

CATEGORY-C

Risk cannot be ruled out. Adequate, well- controlled human

studies are lacking, and animal studies have shown a risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is administered during pregnancy, but the potential benefits may outweigh the potential risk.

Page 41: Teratogenicity dr.elza

CATEGORY - D

Positive evidence of riskStudies in humans, or investigational or post-

marketing data, have demonstrated fetal risk. Nevertheless, potential benefits from the use of the drug may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective

Page 42: Teratogenicity dr.elza

CATEGORY - X

Contraindicated in pregnancy

Studies in animals or humans, or investigational or post-marketing reports, have demonstrated positive evidence of fetal abnormalities or risk that clearly outweighs any possible benefit to the patient. 

Page 43: Teratogenicity dr.elza

CLASSIFICATION BASED ON TERATOGENIC POTENTIAL

Category Characteristics Examples

A Controlled human studies show no risk

Folic AcidThyroxine

B Animal studies OK no human data

Paracetamol, Erythromycin

C Animal studies not OK no human Data

RifampicinMorphine

D Evidence for risk +++Benefits outweigh risk

Antiepileptics

X Evidence for risk +++Risks outweigh benefits

Thalidomide Retinoids

Page 44: Teratogenicity dr.elza

COMMON TERATOGENIC DRUGS

Alchohol Androgens Anticonvulsants Antineoplastics Iodides

IsotretinoinLithium Methimazole Tetracyclines Warfarin

Page 45: Teratogenicity dr.elza

THALIDOMIDE -A LESSON IN MEDICINE PHOCOMELIA : THIS ABNORMALITY ('SEAL LIMBS') CONSISTS OF AN ABSENCE OF DEVELOPMENT OF THE LONG BONES OF THE ARMS AND LEGS

Page 46: Teratogenicity dr.elza

THALIDOMIDE

Developed in Germany in 1954 Promoted as a tranquiliser and anti emetic Taken by thousands of pregnant women Resulted in >10,000 children with birth

deformities Withdrawn in 1961 Has found new uses as an immune

modulator & for multiple myeloma

Page 47: Teratogenicity dr.elza

LESSONS FROM THALIDOMIDE

The placental barrier is not effective against most orally administered drugs

Animal teratogenic testing can be misleading

Page 48: Teratogenicity dr.elza

PHENYTOIN

Cleft lip/palate, microcephaly, mental retardation

Page 49: Teratogenicity dr.elza

VALPROATE

NEURAL TUBE DEFECT

Page 50: Teratogenicity dr.elza

ISOTRETINOIN

Mental retardation and learning disabilities

Eye & ear deformities

Cleft lip, cleft palate & other facial abnormalities

Heart defects

Microcephaly & Hydrocephaly

Page 51: Teratogenicity dr.elza

FETAL ALCOHOL SYNDROME

Page 52: Teratogenicity dr.elza

FETAL WARFARIN SYNDROME

Saddle nose;

retarded growth;

defects of limbs, eyes, central nervous system

Page 53: Teratogenicity dr.elza

YELLOW STAINING OF THE TEETH IN A CHILD EXPOSED TO MATERNAL TETRACYCLINE IN UTERO

Page 54: Teratogenicity dr.elza

DIETHYLSTILBESTROL

In 1971, DES was shown to cause clear cell carcinoma, a rare vaginal tumor in girls and women who had been exposed to this drug in utero.

Page 55: Teratogenicity dr.elza

ANTIBIOTICS• Category A:  None available• Category B: PenicillinsCephalosporinsclindamycinerythromycinmetronidazole- 2nd & 3rd trimesters, contraindicated 1st trimesterazithromycinacyclovir

Page 56: Teratogenicity dr.elza

GASTROINTESTINAL TRACT• Category A: Doxylamine• Category B: rabeprazoledicyclominesucralfatebisacodylloperamidelactulosepantoprazole metoclopramideranitidine ondansetron

Page 57: Teratogenicity dr.elza

ALLERGIC DISORDERS• Category A: Doxylamine• Category B:  chlorpheniramineCyproheptadinemontelukastlevocetirizinecetirizine 

Page 58: Teratogenicity dr.elza

Category Xtestosterone estradiol(dipyridamole/aspirin) 3rd trimester simvastatinlovastatinMisoprostolThalidomideIsotretinoin

Page 59: Teratogenicity dr.elza

TAKEHOME MESSAGES Avoid all drugs during pregnancy unless compelling reasons exist.

Folate therapy during pregnancy can reduce spontaneous as well as drug induced malformations.

Page 60: Teratogenicity dr.elza

THANKYOU